288 related articles for article (PubMed ID: 38004288)
1. The Essential Strategies to Mitigate Cardiotoxicity Caused by Doxorubicin.
Chaulin AM
Life (Basel); 2023 Oct; 13(11):. PubMed ID: 38004288
[TBL] [Abstract][Full Text] [Related]
2. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
[TBL] [Abstract][Full Text] [Related]
3. Mitochondrial Dynamin-Related Protein Drp1: a New Player in Cardio-oncology.
Deng Y; Ngo DTM; Holien JK; Lees JG; Lim SY
Curr Oncol Rep; 2022 Dec; 24(12):1751-1763. PubMed ID: 36181612
[TBL] [Abstract][Full Text] [Related]
4. Primary Cardioprotection Reduces Mortality in Lymphoma Patients with Increased Risk of Anthracycline Cardiotoxicity, Treated by R-CHOP Regimen.
Długosz-Danecka M; Gruszka AM; Szmit S; Olszanecka A; Ogórka T; Sobociński M; Jaroszyński A; Krawczyk K; Skotnicki AB; Jurczak W
Chemotherapy; 2018; 63(4):238-245. PubMed ID: 30372698
[TBL] [Abstract][Full Text] [Related]
5. Prevention of Chemotherapy Induced Cardiomyopathy.
Payne DL; Nohria A
Curr Heart Fail Rep; 2017 Oct; 14(5):398-403. PubMed ID: 28779279
[TBL] [Abstract][Full Text] [Related]
6. Human Pluripotent Stem Cell-Derived Cardiomyocytes for Assessment of Anticancer Drug-Induced Cardiotoxicity.
Schwach V; Slaats RH; Passier R
Front Cardiovasc Med; 2020; 7():50. PubMed ID: 32322588
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological strategies to reduce anthracycline-associated cardiotoxicity in cancer patients.
Stansfeld A; Radia U; Goggin C; Mahalingam P; Benson C; Napolitano A; Jones RL; Rosen SD; Karavasilis V
Expert Opin Pharmacother; 2022 Oct; 23(14):1641-1650. PubMed ID: 36102190
[TBL] [Abstract][Full Text] [Related]
8. Highly potent visnagin derivatives inhibit Cyp1 and prevent doxorubicin cardiotoxicity.
Asnani A; Zheng B; Liu Y; Wang Y; Chen HH; Vohra A; Chi A; Cornella-Taracido I; Wang H; Johns DG; Sosnovik DE; Peterson RT
JCI Insight; 2018 Jan; 3(1):. PubMed ID: 29321375
[TBL] [Abstract][Full Text] [Related]
9. The beneficial role of exercise in preventing doxorubicin-induced cardiotoxicity.
Gaytan SL; Lawan A; Chang J; Nurunnabi M; Bajpeyi S; Boyle JB; Han SM; Min K
Front Physiol; 2023; 14():1133423. PubMed ID: 36969584
[TBL] [Abstract][Full Text] [Related]
10. Strategies to Prevent Cardiotoxicity.
Graffagnino J; Kondapalli L; Arora G; Hawi R; Lenneman CG
Curr Treat Options Oncol; 2020 Apr; 21(4):32. PubMed ID: 32270293
[TBL] [Abstract][Full Text] [Related]
11. Anti-breast cancer-induced cardiomyopathy: Mechanisms and future directions.
Liu C; Chen H; Guo S; Liu Q; Chen Z; Huang H; Zhao Q; Li L; Cen H; Jiang Z; Luo Q; Chen X; Zhao J; Chen W; Yang PC; Wang L
Biomed Pharmacother; 2023 Oct; 166():115373. PubMed ID: 37647693
[TBL] [Abstract][Full Text] [Related]
12. Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management.
Iarussi D; Indolfi P; Casale F; Martino V; Di Tullio MT; Calabrò R
Paediatr Drugs; 2005; 7(2):67-76. PubMed ID: 15871628
[TBL] [Abstract][Full Text] [Related]
13. Cardiotoxic Effect of Modern Anthracycline Dosing on Left Ventricular Ejection Fraction: A Systematic Review and Meta-Analysis of Placebo Arms From Randomized Controlled Trials.
Jeyaprakash P; Sangha S; Ellenberger K; Sivapathan S; Pathan F; Negishi K
J Am Heart Assoc; 2021 Mar; 10(6):e018802. PubMed ID: 33660514
[TBL] [Abstract][Full Text] [Related]
14. Cancer Therapeutics-Related Cardiovascular Complications. Mechanisms, Diagnosis and Treatment.
Oikonomou E; Anastasiou Μ; Siasos G; Androulakis E; Psyrri A; Toutouzas K; Tousoulis D
Curr Pharm Des; 2018; 24(37):4424-4435. PubMed ID: 30636595
[TBL] [Abstract][Full Text] [Related]
15. Telomerase therapy attenuates cardiotoxic effects of doxorubicin.
Chatterjee S; Hofer T; Costa A; Lu D; Batkai S; Gupta SK; Bolesani E; Zweigerdt R; Megias D; Streckfuss-Bömeke K; Brandenberger C; Thum T; Bär C
Mol Ther; 2021 Apr; 29(4):1395-1410. PubMed ID: 33388418
[TBL] [Abstract][Full Text] [Related]
16. Age-Related Considerations in Cardio-Oncology.
Screever EM; Meijers WC; Moslehi JJ
J Cardiovasc Pharmacol Ther; 2021 Mar; 26(2):103-113. PubMed ID: 33124480
[TBL] [Abstract][Full Text] [Related]
17. Cardio-oncology: A Focus on Cardiotoxicity.
Koutsoukis A; Ntalianis A; Repasos E; Kastritis E; Dimopoulos MA; Paraskevaidis I
Eur Cardiol; 2018 Aug; 13(1):64-69. PubMed ID: 30310475
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy-induced cardiotoxicity in children.
Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
[TBL] [Abstract][Full Text] [Related]
19. Update on pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity.
Corremans R; Adão R; De Keulenaer GW; Leite-Moreira AF; Brás-Silva C
Clin Exp Pharmacol Physiol; 2019 Mar; 46(3):204-215. PubMed ID: 30244497
[TBL] [Abstract][Full Text] [Related]
20. Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group.
Seymour L; Bramwell V; Moran LA
Cancer Prev Control; 1999 Apr; 3(2):145-59. PubMed ID: 10474762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
